Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Avastin Dramatically Improves Response, Survival in Deadly Recurrent Glioblastomas

04.09.2009
The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.

Patients with recurrent glioblastoma have a grim prognosis, and conventional treatments were typically limited to largely ineffective and highly toxic chemotherapies. Only about 5 percent of patients respond to further treatment – meaning their tumors shrink by 50 percent or more. And only 15 to 20 percent of patients make it to the six month mark before their disease progresses again. Survival is limited to six to seven months.

But a randomized Phase II study of Avastin alone and Avastin given with CPT-11 have improved those statistics, dramatically increasing response rates, progression-free survival times and overall survival. Early results from the study prompted the U.S. Food and Drug Administration to agree to an accelerated approval of Avastin in May 2009 for use in patients with recurrent glioblastomas, said Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at UCLA’s Jonsson Comprehensive Cancer Center and senior author of the study. The program allows provisional approval of medicines for cancer or other life-threatening diseases.

The study, conducted at 11 centers across the county, was published this week in the early online version of the Journal of Clinical Oncology.

“This is a huge breakthrough for us. In all the years we’ve been treating recurrent glioblastomas using conventional and investigational agents, we’ve never had anything like the responses we’re seeing with Avastin,” said Cloughesy, who also is a professor of neurology. “You just don’t get these kinds of responses in this patient population. We’re seeing dramatic improvements.”

The two-armed study enrolled 167 patients with recurrent glioblastoma. One arm evaluated Avastin used as a single agent, the other Avastin given with CPT-11. An independent radiological facility was used to measure tumor responses, Cloughesy said.

In the Avastin only arm, 28.2 percent of patients responded to the treatment, meaning their tumors shrunk by 50 percent or more, a significant increase from the historic 5 percent response rates. Of the 80 patients, 42.6 percent surpassed the six month mark without their disease progressing, up from the historic 15 to 20 percent of patients. Survival was 9.2 months, a slight increase of the typical six to seven month survival time.

In the arm studying Avastin with CPT-11, 37.8 percent of patients responded to the treatment, while 50.3 percent surpassed the six month progression-free survival mark. Overall survival was 8.7 months, a little less than the Avastin only study.

Cloughesy believes the study shows the apparent power of Avastin when used alone in treating deadly brain cancers for which few effective treatments now exist.

“I think what this tells us is that the majority of the effects we’re seeing are due to the Avastin,” he said.

In addition, Avastin was well tolerated. While some serious side effects were noted – brain hemorrhage, strokes and heart attacks – they were seen in a very small number of patients. Avastin also appeared to reduce brain swelling, allowing patients to significantly lower the steroid dose they had to take, eliminating a number of debilitating side effects.

“Because their brain swelling went down and they could lower their doses of steroids, some patients saw a marked improvement in function,” Cloughesy said.

About 20,000 patients will be diagnosed with glioblastoma this year, of those 14,000 will die.

The last new systemic therapy for recurrent glioblastoma was approved in 1976. Until Avastin, all other experimental therapies tested in this type of cancer failed to meet the FDA guidelines for approval. It’s vital that less toxic, more effective therapies are found to fight glioblastoma, Cloughesy said, both when it recurs and when it is first diagnosed. Studies are underway now to see if the study results can be validated in patients with newly diagnosed glioblastomas.

A significant study finding was that Avastin was nearly as effective alone as it was when given with chemotherapy, but was much better tolerated. In consultation with their doctor, a patient facing less than a year to live might opt for Avastin alone to promote better quality of life and avoid the toxic side effects of chemotherapy.

Avastin is an angiogenesis inhibitor, meaning it cuts off the independent blood supply that a tumor develops to feed and oxygenate itself. A molecularly targeted therapy, Avastin neutralizes vascular endothelial growth factor (VEGF), a chemical signal that stimulates the growth of new blood vessels, or angiogenesis. In addition to recurrent glioblastoma, Avastin has been approved for use in metastatic colorectal, breast and kidney cancers as well as non-small cell lung cancer.

In addition to UCLA’s Jonsson Cancer Center, other institutions participating in the study included the University of California, San Francisco, M.D. Anderson, Dana Farber, Memorial Sloan-Kettering, Duke University, Henry Ford Hospital, the University of Virginia, the University of Chicago, Evanston Northwestern Healthcare and the University of Utah Hospital. The study was funded by Genentech, which manufacturers Avastin.

UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2009, the Jonsson Cancer Center was named among the top 12 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 10 consecutive years.

Kim Irwin | Newswise Science News
Further information:
http://www.cancer.ucla.edu

Further reports about: Avastin CPT-11 Cancer Glioblastomas blood vessel effective treatment kidney cancer survival

More articles from Life Sciences:

nachricht Topologische Quantenchemie
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

nachricht Topological Quantum Chemistry
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>